

Annex 2 & Co GMP Compliance for Biopharmaceuticals

Regulatory Requirements and
Practical Implementation

SPEAKERS:



Dr Markus Fido
Vela Laboratories



Dr Hiltrud Horn
Horn Pharmaceutical Consulting



Stephan Löw
CSL Behring



Dr Daniel Müller
GMP Inspector, German Local Government



Axel Schroeder
Concept Heidelberg



Photo: Courtesy Rentschler Biotechnologie, Laupheim, Germany

16-17 May 2019, Vienna, Austria

HIGHLIGHTS:

- Regulatory Requirements on Biopharmaceuticals
- Validation of Analytical Methods and Processes
- Case Study: Process Transfer from Development to Commercial Production
- Quality Assurance for Biopharmaceuticals
- Case Studies: Hygienic Deviations
- Cleaning Validation in Biopharmaceutical Manufacturing



Annex 2 & Co - GMP Compliance for Biopharmaceuticals

16-17 May 2019, Vienna, Austria

Objectives

This Education Course concentrates on regulatory and practical requirements regarding biopharmaceutical production. From clinical phases to routine manufacturing practical examples and case studies will facilitate the implementation of GMP in your daily business.

The course will treat the topics of routine inspection from regulatory bodies and customers, quality assurance and quality control as well as in laboratory and production.

Speakers from manufacturing, laboratory, consultancy and authority will show their expectations as well as their experiences in GMP implementation.

Background

In defiance of all throwbacks in the last years, a progression of new approvals of biopharmaceuticals is expected. Furthermore after the end of the protection of patents, biotechnical generics will be added.

Especially in the field of biotechnology you find particular challenges to fulfil the regulatory requirements on production and quality assurance.

Industry and authorities are have to face the new and expected changes in the regulatory guidelines.

Target Audience

This course is advisable to people who

- Are involved in regulatory inspections
- Work in quality units at biotech companies
- Implement GMP in biotech production
- Are responsible for GMP requirements pre-approval phases

Moderator

Axel. H. Schroeder, Concept Heidelberg

Programme

GMP Requirements Applying to Biotechnological Investigational Medicinal Products (IMPs of Clinical Phases I-III & APIs for use in IMPs)

- EU regulations & -guidances
- Examples of national regulations
- State-of-the-art manufacturing for clinical phases

GMP Guidelines for Biopharmaceuticals – a brief summary

- Relevant international regulations
- European biotech guidances
- Recent developments & possible impacts

Development of Biopharmaceuticals - GMP and Regulatory Aspects

- GMP and Regulatory Documents
- Ways to Success
- Interaction with Authorities (Meetings/Inspections)

Development, Qualification and Validation of Process Analytics for Biopharmaceuticals

- Relevant Guidelines
- Phases of Product Development / Testing Requirements
- Method Portfolio/Method Development / Method Qualification / Method Validation

GMP Inspections in Biopharmaceutical Production

- Inspections of biopharmaceutical companies
- Focus & discussion points during inspections
 - Clean room classes for biotech facilities
 - Open vs. closed processing
 - Single - vs. multi purpose equipment
 - Cell banking activities
- Inspector's experience, examples of observations

Case Study: Process Transfer from Development to commercial Production

- Key-Aspects for EU and US
- Difference between Development and Commercial Production
- Case Study

Quality Assurance for Biopharmaceuticals

- Classical responsibilities of QA department
- Allocation of responsibilities, training of staff
- Dealing with suppliers & contractors
- The world changes: Change management
- Shit happens: Deviation management & CAPA
- Handling complaints & product recalls
- Paper, paper, paper: documentation works: SOPs, MBR, PQR & management report
- Surveillance of qualification & validation, calibration and maintenance
- Self inspections & auditing

Process Validation in Clinical Phases I-III

- Definition of Validation
- Validation in early Clinical Phase
- Validation in late Clinical Phase
- Validation Documentation
- Guidelines

State-of-the-art biotechnological manufacture (bacteria, yeast, mammalian cells) and cell banking activities - Part 1

- Reasons for cell banking
- Where does GMP start
- Characterization of cell banks
- Storage of cell banks

State-of-the-art biotechnological manufacture (bacteria, yeast, mammalian cells) and cell banking activities - Part 2

- Overview of a typical biotech process
- Requirements on production areas, raw materials and equipment
- Specialities on biotech products
- Fill and finish

Workshop:

Case Studies Hygienic GMP Deviations

- Examples of Pitfalls
- Chemical Interactions
- Human Errors
- Incorrect use

Prevention of cross contamination: dedicated manufacturing or cleaning validation?

- Requirements of Chapter 3 and 5 and Annex 2
- Decision with Consequences: Multipurpose Equipment or Disposables
- Dirt or Product: The Perspective Defines Contamination
- Ways to Remove Contaminants: Cleaning Procedures and their testing
- Risk Based Approach: Crucial Element of the Validation Programme

Social Event



On the first course day, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere

Speakers



Dr Markus Fido,

CEO, Vela Laboratories, Austria

Markus Fido is CEO and Founder of Vela Laboratories. Before that he was Head Quality Control at Igeneon / Apton Biopharma AG and as a Group Leader of Immunology and Product Development at Biomin GmbH, Head Biochemical Control at Baxter AG and Head Quality Operations at Octapharma GmbH. His focus is GMP/GCP concerns during the development of Biopharmaceuticals, Biosimilars and Biologics. He holds a Ph.D. in biochemistry and molecular microbiology from the Technical University in Graz (Austria).



Dr Hiltrud Horn,

Horn Pharmaceutical Consulting, Germany

Dr Hiltrud Horn is managing director of Horn Pharmaceutical Consulting providing consulting services for the pharmaceutical and biotech industry in EU and US. From 1990 to 1999, she worked at Hoffmann-La Roche, Basel in QC/QA and in Regulatory Affairs. In 1999, she joined Knoll AG as Head of "Regulatory Compliance and CMC Documentation". In 2002, she was working as consultant at Cap Gemini Ernst & Young (biotechnology and life sciences) prior to starting her own business.



Stefan Löw,

CSL Behring, Marburg, Germany

Stefan studied bioprocess engineering and is employed at CSL Behring in Marburg. Before this he worked for GSK Vaccine in different positions like Aseptic Expert, Formulation and Filling of Vaccines and Project Management. He started his career at the former Hoechst AG - later Sandoz - with responsibilities in QA Microbiology and aseptic processing of sterile penicillins.



Dr Daniel Müller,

GMP Inspector, Local Government Tübingen

Daniel Müller studied Pharmacy at the University of Würzburg, followed by doctorate. He started working in the pharmaceutical industry in 1998. Among other positions he served as a Qualified Person of large volume parenterals. In 2001 he joined a German inspectorate at Tübingen. Since that time he has been working as a GMP Inspector with focus on biotechnological active ingredients and sterile drug products



Axel H. Schroeder,

Concept Heidelberg, Germany

Axel Schroeder got his degree in Biology at Ruprecht-Karls University Heidelberg. From 1994 to 2005 he worked in the division for Industrial Hygiene and Contamination Control at Ecolab GmbH, Düsseldorf. Between 2005 and 2008 he was engaged at Basan GmbH. Since 2008 he is operation director for microbiology and biotechnology at Concept Heidelberg.



+ 49 6221 84 44 34

Reservation Form (Please complete in full)

Annex 2 & Co - GMP Compliance for Biopharmaceuticals, 16-17 May 2019, Vienna, Austria

Mr Ms

Title, first name, surname

Company

Department

Important: Please indicate your company's VAT ID Number

P.O. No if applicable

Street/P.O. Box

City

Zip Code

Country

Phone/Fax

E-Mail (please fill in)

CONCEPT HEIDELBERG
 P.O. Box 101764
 Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg
GERMANY

General terms and conditions

If you cannot attend the conference you have two options:
 1. We are happy to welcome a substitute colleague at any time.
 2. If you have to cancel entirely we must charge the following processing fees: Cancellation
 - until 2 weeks prior to the conference 10 %
 - within 1 weeks prior to the conference 50 %
 - within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.
Terms of payment: Payable without deductions within 10 days after receipt of invoice.
 German law shall apply. Court of jurisdiction is Heidelberg.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012)

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

Date

Thursday, 16 May 2019 , 09.00 h - 17.30 h
 (Registration and coffee 08.30 h - 09.00 h)
 Friday, 17 May 2019, 08.30 h - 16.30 h

Venue

Radisson Blu Park Royal Palace Hotel Vienna
 Schlossallee 8
 1140 Vienna, Austria
 Phone +43 (1) 891 10 - 0
 Fax: +43 (1) 891 10-9090
 Email: info.parkroyalpalace.vienna@radissonblu.com

Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form/POG when you have registered for the event. Reservation should be made directly with the hotel. Early reservation is recommended.

Fees (per delegate plus VAT)

ECA Members € 1,590
 APIC Members € 1,690
 Non-ECA Members € 1,790
 EU GMP Inspectorates € 895
 Academic Scientists/ Students € 895
 The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Conference Language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.
CONCEPT HEIDELBERG
 P.O. Box 10 17 64
 69007 Heidelberg, Germany
 Phone +49 (0) 62 21/84 44-0
 Fax +49 (0) 62 21/84 44 34
info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content please contact:
 Mr Axel H Schroeder (Operations Manager) at
 +49-62 21 / 84 44 10, schroeder@concept-heidelberg.de

For questions regarding reservation, hotel, organisation, etc. please contact:
 Ms Marion Grimm (Organisation Manager) at
 +49-62 21/84 44 18 or per e-mail at
grimm@concept-heidelberg.de.